A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody -Drug Conjugate, in Patients with Advanced Melanoma
Clinical Trial Grant
Awarded By
Celldex Therapeutics, Inc.
Start Date
October 1, 2015
End Date
July 5, 2019
Awarded By
Celldex Therapeutics, Inc.
Start Date
October 1, 2015
End Date
July 5, 2019